Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Laurence A. Greenbaum, MDPhD, Yahsou Delmas, MD PhD, Fadi Fakhouri, MD PhD, John F. Kincaid, MD MA, Christoph Licht, MD FRCP(C), FASN, Enrico E. Minetti, MD, Chris Mix, MD, Francois Provôt, MD, Eric Rondeau, MD PhD, Neil Sheerin, BSc, MBBS, MRCP, PhD FRCP, Jimmy Wang, PhD, Laurent E. Weekers, MD, Jan Menne, MD

Blood (2015) 126 (23): 2252.

https://doi.org/10.1182/blood.V126.23.2252.2252

Published: 2015

Journal Articles

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, Yahsou Delmas, MD, Maria Herthelius, MD, Camille L. Bedrosian, MD, Chantel Loirat

Blood (2013) 122 (21): 2186.

https://doi.org/10.1182/blood.V122.21.2186.2186

Published: 2013

Journal Articles

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Larry Greenbaum, MD, Christophe M. Legendre, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Frank Eitner, MD, Yahsou Delmas, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 2084.

https://doi.org/10.1182/blood.V120.21.2084.2084

Published: 2012

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD

Blood (2011) 118 (21): 3303.

https://doi.org/10.1182/blood.V118.21.3303.3303

Published: 2011

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Larry Greenbaum, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Osama Gaber, MD, Frank Eitner, MD, Yahsou Delmas, MD, Chantal Loirat, MD, Camille L Bedrosian, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 193.

https://doi.org/10.1182/blood.V118.21.193.193

Published: 2011

NARROW

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Email alerts

ASH Publications

American Society of Hematology

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only